Osimert 80 mg (Tablet)

Unit Price: ৳ 425.00 (1 x 30: ৳ 12,750.00)
Strip Price: ৳ 12,750.00

Medicine Details

Category Details
Generic Osimertinib
Company Everest pharmaceuticals ltd

Title

  • Osimertinib Tablet

Category

  • Oncology
  • Cancer Treatment
  • Pharmaceuticals

DosageForm

  • Tablet

DosageStrength

80 mg

Indications

  • First-line treatment of metastatic non-small cell lung cancer (NSCLC) with specific mutations
  • Treatment of metastatic EGFR T790M mutation-positive NSCLC

ModeOfAction

Kinase inhibitor targeting mutant forms of EGFR

Pharmacology

  • Irreversible binding to mutant EGFR
  • Anti-tumor activity against NSCLC lines harboring EGFR mutations
  • Metabolism through oxidation and dealkylation pathways

Absorption

Median time to C max of 6 hours

Distribution

Mean volume of distribution at steady-state (Vss/F) of 986 L

Elimination

  • Primarily eliminated in the feces (68%)
  • Population estimated mean half-life of 48 hours

Metabolism

  • Mainly through oxidation (CYP3A) and dealkylation
  • Presence of pharmacologically active metabolites in plasma

Excretion

  • Primarily in the feces (68%)
  • Approximately 2% in the urine

Interaction

  • Avoid concomitant administration with strong CYP3A inhibitors and inducers
  • Effects on drugs that are sensitive substrates of CYP3A, BCRP, or CYP1A2

SideEffects

  • Common adverse reactions include diarrhea, rash, dry skin, nail toxicity, stomatitis, fatigue, decreased appetite

PregnancyAndLactation

  • Can cause fetal harm
  • Data on use in pregnant women and presence in human milk are not available
  • Females should use effective contraception during treatment and for 6 weeks after the final dose
  • Males should use effective contraception during and for 4 months following the final dose

PrecautionsAndWarnings

  • Risk of interstitial lung disease (ILD)/pneumonitis
  • Monitoring of QTc interval
  • Assessment of left ventricular ejection fraction (LVEF) before and during treatment
  • Advice on embryo-fetal toxicity
  • Monitoring for adverse reactions in geriatric patients

SpecialPopulations

  • No clinically significant differences based on age, sex, ethnicity, body weight, renal impairment, or hepatic impairment
  • Safety and effectiveness in pediatric patients not established

TherapeuticClass

Cytotoxic Chemotherapy

StorageConditions

  • Store below 30°C
  • Protect from moisture & light
  • Keep out of the reach of children

Related Brands